{"id":32393,"date":"2014-09-30T07:37:00","date_gmt":"2014-09-30T11:37:00","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=32393"},"modified":"2014-09-30T07:37:00","modified_gmt":"2014-09-30T11:37:00","slug":"acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393","title":{"rendered":"AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Reports Regulatory Updates on Zalviso"},"content":{"rendered":"

Boston, MA 09\/30\/2014 (wallstreetpr) \u2013 According to reports, AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)<\/strong> has reported the regulatory updates<\/a> on Zalviso. The main focus of ACRX is on developing and commercializing various innovative therapies and treatment techniques for breakthrough and acute pain. The company is going to resubmit its new drug application (NDA) for Zalviso shortly, for which it has decided to release an update.<\/p>\n

Insights of the matter:<\/strong><\/p>\n

Recently\u00a0AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) held a teleconference call with a few representatives of Food and Drug Administration in order to review the Complete Response Letter of Zalviso, which was received on July 25, 2014. The management of ACRX was so keen to get FDA’s response, and that’s the main reason it proposed FDA to review CRL of Zalviso. It didn’t want to leave any stone unturned; hence, it sent a briefing document to FDA just before the teleconference in order to ensure smooth discussion. FDA representatives provided preliminary comments on the briefing document instantly.<\/p>\n

The teleconference went fine, and\u00a0AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) received good feedback from FDA about protocols, human factors study and bench testing. The company is looking forward to making all the corrections suggested by FDA and resubmit the NDA of Zalviso in the first quarter of 2015. Reporters got in touch with FDA representatives who said that the proposed resubmission would be considered as the class2 resubmission and would carry a review period of six months. Both the parties discussed about various things such as required changes to the Instructions for Use, testing of the mitigations to reduce the incidence of optical system errors and submission of additional data to support the product. After the teleconference,\u00a0AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced that it would acquire bench testing as the perfect approach to evaluating the reduction in OCRs. It would not submit the protocol for the bench testing to FDA for comment and review.<\/p>\n","protected":false},"excerpt":{"rendered":"

Boston, MA 09\/30\/2014 (wallstreetpr) \u2013 According to reports, AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has reported the regulatory updates on Zalviso. The main focus of ACRX is […]<\/p>\n","protected":false},"author":15,"featured_media":32395,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264,263],"tags":[2266,2267],"stock_ticker":[],"class_list":["post-32393","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","category-technology","tag-acelrx-pharmaceuticals-inc-nasdaqacrx","tag-nasdaqacrx","entry"],"acf":[],"yoast_head":"\nAcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Reports Regulatory Updates on Zalviso - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Reports Regulatory Updates on Zalviso - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 09\/30\/2014 (wallstreetpr) \u2013 According to reports, AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has reported the regulatory updates on Zalviso. The main focus of ACRX is […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-09-30T11:37:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/index43.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"400\" \/>\n\t<meta property=\"og:image:height\" content=\"106\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Benjamin Roussey\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Benjamin Roussey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393\"},\"author\":{\"name\":\"Benjamin Roussey\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\"},\"headline\":\"AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Reports Regulatory Updates on Zalviso\",\"datePublished\":\"2014-09-30T11:37:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393\"},\"wordCount\":324,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/index43.jpg\",\"keywords\":[\"AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX)\",\"NASDAQ:ACRX\"],\"articleSection\":[\"Health\",\"Technology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393\",\"name\":\"AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Reports Regulatory Updates on Zalviso - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/index43.jpg\",\"datePublished\":\"2014-09-30T11:37:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/index43.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/index43.jpg\",\"width\":400,\"height\":106},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Reports Regulatory Updates on Zalviso\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\",\"name\":\"Benjamin Roussey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"caption\":\"Benjamin Roussey\"},\"description\":\"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Reports Regulatory Updates on Zalviso - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393","og_locale":"en_US","og_type":"article","og_title":"AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Reports Regulatory Updates on Zalviso - Wall Street PR","og_description":"Boston, MA 09\/30\/2014 (wallstreetpr) \u2013 According to reports, AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has reported the regulatory updates on Zalviso. The main focus of ACRX is […]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-09-30T11:37:00+00:00","og_image":[{"width":400,"height":106,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/index43.jpg","type":"image\/jpeg"}],"author":"Benjamin Roussey","twitter_misc":{"Written by":"Benjamin Roussey","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393"},"author":{"name":"Benjamin Roussey","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d"},"headline":"AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Reports Regulatory Updates on Zalviso","datePublished":"2014-09-30T11:37:00+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393"},"wordCount":324,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/index43.jpg","keywords":["AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX)","NASDAQ:ACRX"],"articleSection":["Health","Technology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393","url":"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393","name":"AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Reports Regulatory Updates on Zalviso - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/index43.jpg","datePublished":"2014-09-30T11:37:00+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/index43.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/index43.jpg","width":400,"height":106},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/acelrx-pharmaceuticals-inc-nasdaqacrx-reports-regulatory-updates-on-zalviso-2-32393#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Reports Regulatory Updates on Zalviso"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d","name":"Benjamin Roussey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","caption":"Benjamin Roussey"},"description":"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/32393","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=32393"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/32393\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/32395"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=32393"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=32393"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=32393"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=32393"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}